Amarin repositions business on cardiovasculars
This article was originally published in Scrip
Executive Summary
Amarin is to license out its CNS pipeline as it repositions its business to focus on cardiovascular disease. The company decided last year to realign its resources and extend its pipeline after disappointing clinical data for its lead candidate Miraxion (AMR101) in Huntington's disease (Scrip Online, December 21st, 2008).